ArticleMembranes2026
Investigation of the Effect of Alkyl Chain Length on the Size and Distribution of Thiol-Stabilized Silver Nanoparticles for Proton Exchange Membrane Fuel Cell Applications.
Article in Membranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent Advances in ZIF-8 Performance for Electrochemical Applications: A Comprehensive Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reports on how the length of the alkyl chain influences the morphological properties of thiol-stabilized silver nanoparticles (Ag NPs) and their subsequent effects on the performance and durability of proton exchange membrane fuel cells (PEMFCs). We synthesized thiol-stabilized Ag NPs by varying the alkyl chain length: 1-hexane thiol (C6), 1-octanethiol (C8), 1-decanethiol (C10), 1-dodecanethiol (C12), and 1-tetradecanethiol (C14), which we achieved using the two-phase Brust-Schiffrin method. X-ray Diffraction (XRD) patterns confirm the formation of crystalline Ag NPs. A morphological study conducted using a Transmission Electron Microscope (TEM) demonstrated that smaller alkyl chain length thiols (C6, C8, and C10) tend to coalesce, while C12 shows better uniformity with no agglomeration. C14 produces larger nanoparticles. A distinct pressure-area isotherm was observed when Ag NPs were spread at the water/air interface of a Langmuir-Blodgett (LB) trough. After obtaining the monolayer formation pressure range, we coated the Nafion 117 membrane of a polymer electrolyte membrane fuel cell with these nanoparticles to form monolayers of different Ag NPs (C6, C8, C12, C14) at various surface pressures (2 mN/m, 6 mN/m and 10 mN/m). Maximum power output enhancement was observed for C12, while other nanoparticles (C6, C8, C10, C14) did not exhibit noticeable power enhancement for PEMFCs. C12 Ag NPs deposited at surface pressure 6 mN/m give maximum power density increase (26.5%) at the fuel cell test station. In addition, we examined the carbon monoxide (CO) resistance test by mixing 0.1% CO with hydrogen (H2), and C12 Ag NPs showed the highest resistance to CO poisoning. However, no enhancement in power or CO tolerance was observed when C12 Ag NPs were coated by spray coating. These outcomes showcase that alkyl chain length plays a critical role in controlling the size and distribution of thiol-stabilized nanoparticles, which eventually has a direct impact on the performance and CO resistance of PEMFCs when applied to polymer electrolyte (Nafion 117). In addition, surface pressure during monolayer formation controls the distribution of Ag NPs (the distance between nanoparticles at the membrane interface), which is necessary to achieve catalytic activity for power improvement and to prevent platinum (Pt) poisoning by CO oxidation at ambient conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.